Choosing the Right Biosimilar for Cancer Care The introduction of biosimilars as anticancer therapies was preceded by a period of supportive care biosimilars. Lee S. Schwartzberg, MD, FACP, describes how he and other clinicians decide which of these agents to use. Well before biosimilar anticancer agents became available, oncologists gained familiarity using biosimilars… Read more »